<i>Background and Objectives</i>: Brolucizumab (IVBr) is a recently introduced anti-vascular endothelial growth factor (anti-VEGF) which has been found to be very effective in treating neovascular age-related macular degeneration (nAMD). This evidence concerns the gene VEGFA and wet macular degeneration.